Virios Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Related Parties

Related Parties	9 Months Ended
Sep. 30, 2021
Related Parties
Related Parties	9Related Parties The Company uses Gendreau Consulting, LLC, a consulting firm (“Gendreau”), for drug development, clinical trial design, and planning, implementation and execution of contracted activities with the clinical research organization. Gendreau’s managing member became the Company’s Chief Medical Officer (“CMO”) effective January 1, 2021. The Company has and will continue to contract the services of the CMO’s spouse through the firm to perform certain activities in connection with the Company’s ongoing clinical trial in FM. During the three and nine months ended September 30, 2021 and 2020, the Company paid Gendreau $91,335 and $233,616, respectively, and $0 and $450, respectively, and had accounts payable of $29,443 and $7,916 to Gendreau as of September 30, 2021 and December 31, 2020, respectively.

Related Parties

9 Months Ended

Sep. 30, 2021

9Related Parties

The Company uses Gendreau Consulting, LLC, a consulting firm (“Gendreau”), for drug development, clinical trial design, and planning, implementation and execution of contracted activities with the clinical research organization. Gendreau’s managing member became the Company’s Chief Medical Officer (“CMO”) effective January 1, 2021. The Company has and will continue to contract the services of the CMO’s spouse through the firm to perform certain activities in connection with the Company’s ongoing clinical trial in FM. During the three and nine months ended September 30, 2021 and 2020, the Company paid Gendreau $91,335 and $233,616, respectively, and $0 and $450, respectively, and had accounts payable of $29,443 and $7,916 to Gendreau as of September 30, 2021 and December 31, 2020, respectively.